Skip Nav Destination
Issues
1 October 2018
-
Cover Image
Cover Image
About the CoverClose Modal
The efficacy of immunotherapy can be limited by immunosuppressive mechanisms in the tumor microenvironment. One such mechanism that is exploited by tumor cells is the production of adenosine, which creates an immunosuppressive niche that inhibits the functions of multiple immune cell types. Willingham et al. developed an adenosine receptor antagonist, CPI-444. In multiple tumor models, comparison of mice with and without CPI-444 treatment demonstrates that the compound, administered as a single agent, neutralized adenosine-mediated suppression, resulting in reduced tumor growth, increased antitumor responses, and increased T-cell activation. When combined with immune checkpoint blockade, antitumor responses and tumor reduction were enhanced. Thus, CPI-444 is a potential therapeutic for solid tumors. Read more in this issue on page 1136. Original image is of CD73 expression in non–small cell lung cancer. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2326-6066
EISSN 2326-6074
Journal Archive
Cancer Immunology Research (2013-Present)
(ISSN 2326-6066) Published monthly since 2013.Cancer Immunity (2001-2013; volumes 1-13)
(EISSN 1424-9634) Published periodically from 2001-2013.Table of Contents
What We’re Reading
Cancer Immunology at the Crossroads
Cancer Immunology Miniature
Research Articles
Author Choice
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
Stephen B. Willingham; Po Y. Ho; Andrew Hotson; Craig Hill; Emily C. Piccione; Jessica Hsieh; Liang Liu; Joseph J. Buggy; Ian McCaffery; Richard A. Miller
Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model
Sophie M. Poznanski; Tina Nham; Marianne V. Chew; Amanda J. Lee; Joanne A. Hammill; Isabella Y. Fan; Martin Butcher; Jonathan L. Bramson; Dean A. Lee; Hal W. Hirte; Ali A. Ashkar
GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model
Simran S. Sabharwal; David B. Rosen; Jeff Grein; Dana Tedesco; Barbara Joyce-Shaikh; Roanna Ueda; Marie Semana; Michele Bauer; Kathy Bang; Christopher Stevenson; Daniel J. Cua; Luis A. Zúñiga
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
Dennis O. Adeegbe; Shengwu Liu; Maureen M. Hattersley; Michaela Bowden; Chensheng W. Zhou; Shuai Li; Raven Vlahos; Michael Grondine; Igor Dolgalev; Elena V. Ivanova; Max M. Quinn; Peng Gao; Peter S. Hammerman; James E. Bradner; J. Alan Diehl; Anil K. Rustgi; Adam J. Bass; Aristotelis Tsirigos; Gordon J. Freeman; Huawei Chen; Kwok-Kin Wong
Author Choice
Maelstrom Directs Myeloid-Derived Suppressor Cells to Promote Esophageal Squamous Cell Carcinoma Progression via Activation of the Akt1/RelA/IL8 Signaling Pathway
Pupu Li; Xinfeng Chen; Guohui Qin; Dongli Yue; Zhen Zhang; Yu Ping; Dan Wang; Xuan Zhao; Mengjia Song; Qitai Zhao; Jieyao Li; Shasha Liu; Dong Wang; Chaoqi Zhang; Jingyao Lian; Ling Cao; Feng Li; Lan Huang; Liping Wang; Li Yang; Jianmin Huang; Hong Li; Bin Zhang; Yi Zhang
Advertisement